期刊文献+

抗结核治疗后RT027型艰难梭菌致伪膜性肠炎1例 被引量:3

One case report of pseudomembranous colitis caused by RT027 Clostridioides difficile after antituberculosis treatment
下载PDF
导出
摘要 艰难梭菌(Clostridioides difficile)是一种专性厌氧革兰阳性芽孢杆菌,是造成医院内抗生素相关性腹泻的重要病原菌[1]。长期使用广谱抗生素、免疫抑制剂、质子泵抑制剂或化疗药物等可导致肠道菌群失调,造成产毒艰难梭菌过度繁殖并产生毒素引起艰难梭菌相关性腹泻(Clostridioides difficile associated diarrhea,CDAD)。CDAD的症状轻重不一,可从轻度的腹泻到重度的伪膜性肠炎,甚至引起感染性休克导致死亡[2]。近年来,艰难梭菌高产毒株RT027型在欧洲和北美地区造成了医院感染的暴发流行,引起了世界范围的关注[3]。在国内该型别的报道较少,仅在北京、广州、香港、台湾等地区有少量散发病例报道[4-9]。本文报道1例抗结核治疗后RT027型艰难梭菌引起伪膜性肠炎的病例。
作者 杨靖 尹凯歌 李雅静 强翠欣 牛亚楠 李志荣 赵宝鑫 赵建宏 YANG Jing;YIN Kaige;LI Yajing;QIANG Cuixin;NIU Yanan;LI Zhirong;ZHAO Baoxin;ZHAO Jianhong(Hebei Provincial Center for Clinical Laboratories,Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)
出处 《中国感染与化疗杂志》 CAS CSCD 北大核心 2020年第2期212-215,共4页 Chinese Journal of Infection and Chemotherapy
基金 河北省卫计委重点课题计划(20170533) 河北省科技厅国际合作项目(183977118D)。
  • 相关文献

参考文献3

二级参考文献13

  • 1Walter E. Longo M.D.,John E. Mazuski M.D.,Katherine S. Virgo Ph.D.,Paul Lee M.D.,Anil N. Bahadursingh M.D.,Frank E. Johnson M.D..Outcome After Colectomy for Clostridium Difficile Colitis[J]. Diseases of the Colon & Rectum . 2004 (10)
  • 2Coia JE. What is the role of antimicrobial resistance in the new epidemic of CIostridiun difficile [ J ]. Int I Antimicrob Agents, 2009, 33 ( Suppl 1 ) : S9-12. DOI: 10. 1016/S0924-8579 (09) 70009-3.
  • 3Surawicz CM, Alexander J. Treatment of refraeto and recurrent Clostridium dificile infection[ J]. Nat Rev Gastroenterol Hepatol, 2011, 8(6) : 330-339. DOI: 10. 1038/nrgastro. 2011.59.
  • 4Lihua Z1, Danfeng D, Cen J, et al. Clinical eharacterization and risk factors of Clostridiurn diJficile infection in elderly palients in a Chinese hospital[J]. J Infect Dev Ctries,2015, 9(4) : 381-387. DOI: 10. 3855/jide. 4816.
  • 5Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria [ S ] Approved Standard: M l l-A7. Wayne,PA :CLSI, 2010.
  • 6Zheng L,Keller SF,Lyerly DM,et al. Muhicenter evaluation of a new screening test 1hat detects Clostridium difficile in fecal specimens [ J ]. J Clin Microbiol, 2004, 42 ( 8 ) : 3837-3840. DOI: 10. 1128/JCM. 42. 8. 3837-3840. 2004.
  • 7Epstein L, Golan Y. Fidaxmiei, a new treatment for C[ostridittm diflcile infections[J]. Drugs Today(Barc) , 2012, 48(2) : 101- 108. DOI: 10. 1358/dot. 2012.48.21746740.
  • 8Liao CH, Ko WC, Lu JJ, et al. Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin ( OPT-80 ) and rifaximin : a multicenter study in Taiwan [ J ]. Antimicrob Agents Chemother, 2012, 56 ( 7 ) : 3943-3949. OOl: 10. 1128/ AAC. 00191-12.
  • 9Lachowicz D, Pituch H, Obuch-Woszczatyfiski P. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012 [ J ]. Anaerobe, 2015, 31: 37-41. DOI: 10. 1016/ j. anaerobe. 2014.09. 004.
  • 10Kuwata Y,Tanimoto S, Sawabe E, et al. Molecular epidemiology and antinficrobial susceptibility of Clostridium diJftcile isolated from a university teaching hospital in Japan [ J ]. Eur J Clin Microbiol Infect Dis, 2015, 34(4) : 763-772. DOI: 10. 1007/ s10096-.014-2290-9.

共引文献131

同被引文献22

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部